This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
by Zacks Equity Research
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Top Research Reports: Chevron, AbbVie, Phillips 66 & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), AbbVie (ABBV) and Phillips 66 (PSX).
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Momenta (MNTA) reports a wider loss and misses on sales in Q2 .
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.
Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%
by Zacks Equity Research
Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 2.26% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AstraZeneca (AZN) Jumps: Stock Rises 5.7%
by Zacks Equity Research
AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2019 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.
Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?
by Christopher Vargas
Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
Should You Buy AbbVie (ABBV) Ahead of Earnings?
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.
Use Rising P/E Strategy to Buy 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.